Listed

Cardiol Therapeutics Inc.: Form 40-F/A for the period ended Dec 31, 2021

Filed with the SEC on Apr 20, 2022 and accepted by EDGAR at Apr 20, 2022, 16:49 ET.

Share

Share this page

Story card, 1080 × 1920

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Line itemPeriodValueXBRL concept
Revenue12 months2021-01-01 to 2021-12-31CAD 78.8kifrs-full:Revenue
Operating income12 months2021-01-01 to 2021-12-31−CAD 38.7mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2021-01-01 to 2021-12-31CAD 0ifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2021-01-01 to 2021-12-31−CAD 31.6mifrs-full:ProfitLoss
Diluted EPS12 months2021-01-01 to 2021-12-31−CAD 0.73ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2021-01-01 to 2021-12-31−CAD 0.73ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2021-01-01 to 2021-12-31−CAD 23.6mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31CAD 12.9kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2021-12-31CAD 83.9mifrs-full:CashAndCashEquivalents
Current assetsAt period end2021-12-31CAD 87.1mifrs-full:CurrentAssets
Total assetsAt period end2021-12-31CAD 87.9mifrs-full:Assets
Current liabilitiesAt period end2021-12-31CAD 11.6mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2021-12-31CAD 11.6mifrs-full:Liabilities
Shareholders' equityAt period end2021-12-31CAD 76.2mifrs-full:Equity
Shares outstandingAt period end2021-12-3161,922,999 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001104659-22-047891. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.